Pioneering NAFLD/NASH Early-phase Clinical Pharmacology Study Designs

DISCOVERY TRACK

CO-CHAIRS:

Lorraine Rusch, PhD, President, High Point Clinical Trials Ctr

Sabina Paglialunga, PhD, Metabolic & Pharmacodynamic Specialist, Celerion

TARGET AUDIENCE:

This Symposium will be useful for clinical pharmacologists, physicians, metabolic scientists, hepatologists, research scientists, medical directors and bioanalytical scientists.

GOALS AND OBJECTIVES:

Following completion of this activity, the learner will be able to:

1. Implement study design considerations and discuss safety concerns for clinical NAFLD/NASH studies;
2. Compare invasive and non-invasive NAFLD/NASH measurements for diagnosis and treatment response assessments;
3. Explore strategic NAFLD/NASH biomarkers and implementation of these measurements in clinical studies and medical practice.

4:00 – 4:10 pm

Introduction

Lorraine Rusch, PhD, President, High Point Clinical Trials Ctr

4:10 – 4:30 pm

Non-invasive Approaches to Diagnosing & Evaluating Treatment Response in NAFLD & NASH

Dina Halegoua-De Marzio, MD, Assistant Professor of Medicine & Jefferson Fatty Liver Ctr Director, Thomas Jefferson Univ Hosp

4:30 – 4:50 pm

Leveraging Soluble Biomarkers for NAFLD/NASH Studies

Amar Sethi, MD, PhD, President & Chief Scientific Officer, Pacific Biomarkers Inc

4:50 – 5:10 pm

Optimizing NAFLD/NASH Study Design in Early Clinical Trials

Sabina Paglialunga, PhD, Metabolic & Pharmacodynamic Specialist, Celerion

5:10 – 5:30 pm

Panel Discussion and Q&A